EU Avastin Court Ruling Deals Yet Another Blow To Novartis

In the latest in a string of knockbacks for both Novartis and Roche, the EU’s highest court has said that the Italian authorities are within their rights to reimburse Roche’s Avastin for wet AMD, even though it is not approved for that indication.

Scanning
Italy can reimburse Avastin for off-label ophthalmic use, says EU court • Source: Shutterstock

The Court of Justice of the EU has ruled that Italy’s decision to reimburse Roche’s Avastin (bevacizumab) for off-label use in wet age-related macular degeneration is not contrary to EU law. 

The decision is yet another blow to Novartis AG, which together with Roche is involved in a long-running, and...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Italy

More from Europe